Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Cadrenal Therapeutics received official minutes from its FDA End-of-Phase 2 meeting, establishing the path to advance CAD-1005 directly into a pivotal Phase 3 registration trial for HIT. The randomized, placebo-controlled study is planned for approximately 120 patients worldwide, with a primary endpoint of new or worsening thrombotic events and a target NDA submission in 2029.
Key figures
- Cash
- 2308137
- Ga expenses
- 1742315
- Rd expenses
- 771508
- Phase 3 patients
- 120
- Financing proceeds
- 2500000
- Operating expenses
- 2514378
- Projected nda submission
- 2029
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.